Al-hamadany, N., Azubaidy, M. (2023). Sub-acute Effects of α-Fe2O3 Nanoparticles on Some Biochemical Parameters in Mice. Journal of Applied Veterinary Sciences, 8(3), 46-53. doi: 10.21608/javs.2023.210749.1232
Nashwan Adnan Al-hamadany; Muna Hazim Azubaidy. "Sub-acute Effects of α-Fe2O3 Nanoparticles on Some Biochemical Parameters in Mice". Journal of Applied Veterinary Sciences, 8, 3, 2023, 46-53. doi: 10.21608/javs.2023.210749.1232
Al-hamadany, N., Azubaidy, M. (2023). 'Sub-acute Effects of α-Fe2O3 Nanoparticles on Some Biochemical Parameters in Mice', Journal of Applied Veterinary Sciences, 8(3), pp. 46-53. doi: 10.21608/javs.2023.210749.1232
Al-hamadany, N., Azubaidy, M. Sub-acute Effects of α-Fe2O3 Nanoparticles on Some Biochemical Parameters in Mice. Journal of Applied Veterinary Sciences, 2023; 8(3): 46-53. doi: 10.21608/javs.2023.210749.1232
Sub-acute Effects of α-Fe2O3 Nanoparticles on Some Biochemical Parameters in Mice
Department of Physiology, Biochemistry and Pharmacology, College of Veterinary Medicine, University of Mosul, Mosul, Iraq
Receive Date: 13 May 2023,
Revise Date: 15 June 2023,
Accept Date: 21 June 2023
Abstract
The goal of the study was to find out the toxic effect of daily treatment with α-Fe2O3 nanoparticles for 14 and 28 days on some biochemical indicators in mice by measuring ferritin, transferrin, cholinesterase enzyme activity, the concentration of Caspase-3, and the concentration of glutathione and malondehyde in brain and liver tissues at doses of 75, 150 and 300 mg/kg. α-Fe2O3 nanoparticles at the dose of 75 mg/kg caused a significant decrease in the activity of the acetyl cholinesterase enzyme in the brain and liver after 14 days of treatment, compared with the control group and the doses of α- Fe2O3 (75, 150, and 300 mg/kg) led to a significant decrease in the activity of the acetyl cholinesterase enzyme in the brain after 28 days of treatment. Fe2O3 at a dose of 75 mg/kg on the 14th day and at a dose of 150 mg/kg on the 28th day of treatment resulted in a significant increase in the caspase-3 enzyme in the brain compared to the control group. While the doses of 150 and 300 mg/kg for 28 days led to a significant increase in transferrin concentration compared with the control group, The α-Fe2O3 nanoparticles at doses of 75, 150, and 300 mg/kg for 28 days caused a significant decrease in the concentration of glutathione in the liver and brain tissues compared with the control group, accompanied by a significant increase in the concentration of malondehyde in the brain and liver tissues at doses of 150 and 300 mg/kg of body weight. We conclude that repeated exposure to α - Fe2O3 nanoparticles has toxic effects on vital organs such as the brain and liver, represented by a decrease in the concentration of acetylcholinesterase and its ability to induce oxidative stress through a decrease in glutathione concentration and an increase in malondehyde concentration in mice .
Al-ZUBAIDY, M. H., MOUSA, Y.J., HASAN, M.M., and MOHAMMAD, F.K., 2011. Acute toxicity of veterinary and agricultural formulations of organophosphates dichlorvos and diazinon in chicks. Archives of Industrial Hygiene and Toxicology. 62:317-323. http://dx.doi.org/10.2478/10004-1254-62-2011-2139
Al-ZUBAIDY, M.H., and AMIN, S.M., 2018. Cholinesterase inhibition in chicks treated with manganese chloride. Iraqi Journal of Veterinary Sciences, .32(2). https://doi.org/10.33899/ijvs.2019.153875
BRILEY- SAEBO, K., BJORNERUD, A., GRANT, D., AHLSTROM, H., BERG, T., and KINDBERG, G.M., 2004. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell and Tissue Research, 316, 315–323.https://doi.org/10.1007/s00441-004-0884-8
BUZEA, C., PACHECO, I.I., and ROBBIE, K., 2007. Nano-materials and nanoparticles: sources and toxicity. Biointerphases. 2(4):MR17–MR71. https://doi.org/10.1116/1.2815690
DALLE-DONNE, I., ROSSI, R., COLOMBO, R., GIUSTARINI, D., and MILZANI, A., 2006. Biomarkers of oxidative damage in human disease. Clinical Chemistry, 52(4), 601–623. https://doi.org/10.1373/clinchem.2005.061408
DHAKSHINAMOORTHY, V., MANICKAM, V., and PERUMAL, E., 2017. Neurobehavioural toxicity of iron oxide nanoparticles in mice. Neurotoxicity Research, 32(2), 187–203. https://doi.org/10.1007/s12640-017-9721-1
DOMINGUEZ-VERSA, J. M., FERNANDEZ, B., and GALVEZ, N., 2010. Native and synthetic ferritins for nanobiomedical applications: recent advances and new perspectives. Future Medicinal Chemistry, 2(4), 609–618. https://doi.org/10.4155/fmc.09.171
ELSHEMY, M. A. 2018. Iron oxide nanoparticles versus ferrous sulfate in treatment of iron deficiency anemia in rats. Egyptian Journal of Veterinary Sciences, 49(2), 103–109. https://doi.org/10.21608/ejvs.2018.3855.1039
ESPANANI, H.R., FAZILATI, M., SADEGHI, L., YOUSEFIBABADI, V., BAKHIANI, S.A.E., and AMRAIE, E., 2013. Investigation the zinc oxide nanoparticle’s effect on sex hormones and cholesterol in rat. International Research Journal of Biological Sciences, 2(8), 54–58. https://doi.org/10.1093/nutrit/nuv059
GUPTA, A. K., and GUPTA, M., 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26(18), 3995–4021. https://doi.org/10.1016/J.BIOMATERIALS.2004.10.012
HALLIWELL, B. 1992. Oxygen radicals as key mediators in neurological disease: fact or fiction? Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 32(S1), S10–S15. https://doi.org/10.1002/ana.410320704
HALLIWELL, B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs & Aging, 18, 685–716.https://doi.org/10.2165/00002512-200118090-00004
INDIRA, T.K., and LAKSHMI, P.K., 2010. Magnetic nanoparticles–a review. International Journal of Pharmaceutical Sciences and Nanotechnology, 3(3), 1035–1042 .https://doi.org/10.3109/21691401.2015.1014093
ITO, A., SHINKAI, M., HONDA, H., and KOBAYASHI, T., 2005. Medical application of functionalized magnetic nanoparticles. Journal of Bioscience and Bioengineering, 100(1), 1–11. https://doi.org/10.1263/jbb.100.77
JACOBS, A., and WORWOOD, M., 1975. Ferritin in serum: clinical and biochemical implications. New England Journal of Medicine, 292(18), 951–956. https://doi.org/10.1056/nejm197505012921805
KELL, D. B., and PRETORIUS, E., 2014. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics, 6(4), 748–773. https://doi.org/10.1039/c3mt00347g
KUMARI, M., RAJAK, S., SINGH, S.P., KUMARI, S. I., KUMAR, P.U., MURTY, U.S.N., MAHHOOB, M., GROVER, P., and RAHMAN, M.F., 2012. Repeated oral dose toxicity of iron oxide nanoparticles: biochemical and histopathological alterations in different tissues of rats. Journal of Nanoscience and Nanotechnology, 12(3), 2149–2159. https://doi.org/10.1166/jnn.2012.5796
KUMARI, M., RAJAK, S., SINGH, S. P., MURTY, U.S.N., MAHHOOB, M., GROVER, P., and RAHMAN, M.F., 2013. Biochemical alterations induced by acute oral doses of iron oxide nanoparticles in Wistar rats. Drug and Chemical Toxicology, 36(3), 296–305. https://doi.org/10.1166/jnn.2012.5796
LEE, M.J.E., VEISEH, O., BHATTARAI, N., SUN, C., HANSEN, S.J., DITZLER, S., KNOBLAUGH, S., LEE, D., ELLENBOGEN, R., and ZHANG, M., 2010. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PloS One, 5(3), e9536. https://doi.org/10.1021/nn1008512
LIANG, L., COOK, W.D., and ZHU, J., 2008. DEA models for two‐stage processes: Game approach and efficiency decomposition. Naval Research Logistics (NRL), 55(7), 643–653. https://doi.org/10.1002/NAV.20308
LIU, Y., LI, J., XU, K., GU, J., HUANG, L., ZHANG, L., LIU, N., KONG, J., XING, M., and ZHANG, L., 2018. Characterization of superparamagnetic iron oxide nanoparticle-induced apoptosis in PC12 cells and mouse hippocampus and striatum. Toxicology Letters, 292, 151–161.https://doi.org/10.1016/j.toxlet.2018.04.033
LOEFFLER, D.A., CONNOR, J.R., JUNEAU, P.L., SNYDER, B.S., KANALEY, L., DEMAGGIO, A.J., NGUYEN, H., BRICKMAN, C.M., and LEWITT, P.A., 1995. Transferrin and iron in normal, Alzheimer’s disease, and Parkinson’s disease brain regions. Journal of Neurochemistry, 65(2), 710–716.https://doi.org/10.1046/j.1471-4159.1995.65020710.x
LU, M., COHEN, M.H., RIVES, D., and PAZDUR, R., 2010. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology, 85(5), 315–319. https://doi.org/10.1002/ajh.21656
MIURA, N., and SHINOHARA, Y., 2009. Cytotoxic effect and apoptosis induction by silver nanoparticles in HeLa cells. Biochemical and Biophysical Research Communications, 390(3), 733–737. https://doi.org/10.1016/j.bbrc.2009.10.039
MOHAMMAD, F.K., Al-ZUBAIDY, M.H., and ALIAS, S.A. 2007. Electrometric Determination of Erythrocyte, Plasma and Whole Blood Cholinesterase Activities in Sheep, Goats and Cattle and Their in vitro Inhibition by Anticholinesterase Insecticides. Journal of Pharmacology and Toxicology,2(2),131-141. https://doi.org/10.3923/JPT.2007.131.141
NEL, A., XIA, T., MADLER, L., and LI, N., 2006. Toxic potential of materials at the nanolevel. Science, 311(5761), 622–627. https://doi.org/10.1126/science.1114397
OHKAW, H., OHISI, N., and YAGI, K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95(2), 351–358. https://doi.org/10.1016/0003-2697(79)90738-3
REDDY, U.A., PRABHAKAR, P.V, and MAHBOOB, M., 2017. Biomarkers of oxidative stress for in vivo assessment of toxicological effects of iron oxide nanoparticles. Saudi Journal of Biological Sciences, 24(6), 1172–1180. https://doi.org/10.1016/j.sjbs.2015.09.029
ROMANO, D., BONOMI, F., DE MATTOS, M.C., DE SOUSA, FONSECA, T., DE OLIVEIRA, M.C., and MOLINARI, F., 2015. Esterases as steroselective biocatalysts. Biotechnology Advances 33(5): 547-565. https://doi.org/10.1016/j.biotechadv.2015.01.006
ROUAULT, T.A., and TONG, W.H., 2008. Iron–sulfur cluster biogenesis and human disease. Trends in Genetics, 24(8), 398–407. https://doi.org/10.1016/j.tig.2008.05.008
VOSS, L., HOCHE, E., STOCK, V., BOHMERTHMERT, L., BRAEUNING, A., THUENEMANN, A. F., and SIEG, H., 2021. Intestinal and hepatic effects of iron oxide nanoparticles. Archives of Toxicology, 95, 895–905. https://dx.doi.org/10.1007/s00204-020-02960-7
WANG, B., FENG, W.Y., WANG, M., SHI, J.W., ZHANG, F., OUYANG, H., ZHAO, Y.L., CHAI, Z.F., HUANG, Y.Y., and XIE, Y.N., 2007. Transport of intranasally instilled fine Fe2O3 particles into the brain: micro-distribution, chemical states, and histopathological observation. Biological Trace Element Research, 118(3), 233–243. https://doi.org/10.1007/s11051-007-9245-3
WANG, W., KNOVICH, M.A., COFFMAN, L.G., TORTI, F.M., and TORTI, S.V., 2010. Serum ferritin: past, present and future. Biochimica et Biophysica Acta (BBA)-General Subjects, 1800(8), 760–769.
YEH, Y.C., CRERAN, B., and ROTELLO, V.M., 2012. Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale, 4(6), 1871–1880. http://dx.doi.org/10.1039/c1nr11188d
ZHU, M.T., FENG, W.Y., WANG, Y., WANG, B., WANG, M., OUYANG, H., ZHAO, Y.L., and CHAI, Z.F., 2009. Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment. Toxicological Sciences, 107(2), 342–351.
View on SCiNiTO
Top